Investors Urged to Join Class Action Against Cerevel Therapeutics Over Alleged Shareholder Fraud
On May 16, 2025, Levi & Korsinsky, LLC announced a significant class action lawsuit targeting Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). This legal action aims to address concerns from investors who faced financial losses due to alleged securities fraud perpetuated during a critical merger with AbbVie Inc. The deadline for investors to participate in this case is set for June 3, 2025.
The lawsuit claims that Cerevel Therapeutics misled investors, resulting in major financial detriment during a key period, specifically from October 11, 2023, through August 1, 2024. The class action represents individuals or entities who sold their shares during this timeframe or held shares during a critical merger vote on January 8, 2024.
At the center of the allegations is Aureate’s controversial October 16, 2023 secondary stock offering. According to the complaint, the documents associated with this offering failed to disclose vital facts regarding AbbVie’s interest in acquiring Cerevel at a significantly higher price than the initial share offering price of $22.81. This omission severely impacted Cerevel's stock price until the merger announcement took place, effectively misleading investors about the true market position of the shares.
Moreover, Bain Capital Investors, LLC, Cerevel's controlling shareholder, allegedly purchased shares at this artificially reduced price while possessing crucial non-public information about AbbVie's impending acquisition. This strategic move allowed Bain to benefit immensely when Cerevel announced the merger at a price of $45 per share on December 6, 2023, resulting in an unexpected profit exceeding $120 million on their shares acquired at the lower offering price.
Investors who suffered financial losses due to the aforementioned circumstances are encouraged to contact Levi & Korsinsky to facilitate their inclusion as lead plaintiffs in the class action. It is important to note that being a lead plaintiff is not a prerequisite for participating in the recovery process, and affected individuals can seek compensation without bearing any personal financial costs or obligations.
Levi & Korsinsky boasts a successful track record spanning over two decades in securities litigation, having recovered hundreds of millions for aggrieved shareholders. The firm has garnered recognition within the top ranks of securities litigation firms in the United States as per ISS Securities Class Action Services. With an extensive team working devotedly, investors can expect comprehensive support in navigating the complexities of the lawsuit.
To understand the full scope of the lawsuit and how to participate, investors can refer to the official website or reach out directly to Levi & Korsinsky. The firm has indicated that they are ready to assist individuals in submitting their claims and offer clarity on the process involved in this class action.
In summary, for anyone affected by Cerevel Therapeutics’ stock offerings and subsequent merger with AbbVie, the upcoming deadline on June 3, 2025, marks a pivotal moment for seeking justice and recovering losses. Investors are urged not to miss this opportunity to potentially hold the company accountable for the alleged misstatements that led to significant financial consequences.
Background of the Case
The lawsuit claims that Cerevel Therapeutics misled investors, resulting in major financial detriment during a key period, specifically from October 11, 2023, through August 1, 2024. The class action represents individuals or entities who sold their shares during this timeframe or held shares during a critical merger vote on January 8, 2024.
At the center of the allegations is Aureate’s controversial October 16, 2023 secondary stock offering. According to the complaint, the documents associated with this offering failed to disclose vital facts regarding AbbVie’s interest in acquiring Cerevel at a significantly higher price than the initial share offering price of $22.81. This omission severely impacted Cerevel's stock price until the merger announcement took place, effectively misleading investors about the true market position of the shares.
Moreover, Bain Capital Investors, LLC, Cerevel's controlling shareholder, allegedly purchased shares at this artificially reduced price while possessing crucial non-public information about AbbVie's impending acquisition. This strategic move allowed Bain to benefit immensely when Cerevel announced the merger at a price of $45 per share on December 6, 2023, resulting in an unexpected profit exceeding $120 million on their shares acquired at the lower offering price.
What Investors Should Know
Investors who suffered financial losses due to the aforementioned circumstances are encouraged to contact Levi & Korsinsky to facilitate their inclusion as lead plaintiffs in the class action. It is important to note that being a lead plaintiff is not a prerequisite for participating in the recovery process, and affected individuals can seek compensation without bearing any personal financial costs or obligations.
Levi & Korsinsky boasts a successful track record spanning over two decades in securities litigation, having recovered hundreds of millions for aggrieved shareholders. The firm has garnered recognition within the top ranks of securities litigation firms in the United States as per ISS Securities Class Action Services. With an extensive team working devotedly, investors can expect comprehensive support in navigating the complexities of the lawsuit.
Next Steps
To understand the full scope of the lawsuit and how to participate, investors can refer to the official website or reach out directly to Levi & Korsinsky. The firm has indicated that they are ready to assist individuals in submitting their claims and offer clarity on the process involved in this class action.
In summary, for anyone affected by Cerevel Therapeutics’ stock offerings and subsequent merger with AbbVie, the upcoming deadline on June 3, 2025, marks a pivotal moment for seeking justice and recovering losses. Investors are urged not to miss this opportunity to potentially hold the company accountable for the alleged misstatements that led to significant financial consequences.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.